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Abstract
Background: Sepsis is a potentially fatal syndrome mediated by an early [e.g., tumor necrosis factor-alpha (TNF-α)]
and late [high mobility group box-1 (HMGB-1)] proinflammatory cytokine response to infection. Sepsis-induced
acute kidney injury (AKI) is associated with a high mortality. C-Fos/activator protein-1 (AP-1) controls the
transactivation of proinflammatory cytokines via AP-1 binding in the promoter region. T-5224 is a de novo small
molecule inhibitor of c-Fos/AP-1 that controls gene expression of multiple proinflammatory cytokines. We
investigated whether T-5224, a selective inhibitor of c-Fos/AP-1, improves survival in lethal lipopolysaccharide
(LPS)-induced AKI by inhibiting early (TNF-α) and late (HMGB-1) proinflammatory cytokine response.
Methods: Mice were divided into four groups (control, LPS, LPS + T-5224, and T-5224 only). Control mice were
administered polyvinylpyrrolidone (PVP) solution orally, immediately after intraperitoneal (i.p.) saline injection. LPS mice
were administered PVP solution orally immediately after i.p. LPS (10 mg/kg) injection. LPS + T-5224 mice were
administered T-5224 orally (300 mg/kg) immediately after i.p. LPS injection. T-5224 mice were administered T-5224
orally (300 mg/kg) after i.p. saline injection. Serum concentrations of TNF-α, HMBG-1, and interleukin (IL)-10 were
measured by enzyme-linked immunosorbent assay (ELISA). Serum blood urea nitrogen (BUN) and creatinine
concentrations were commercially analyzed. Finally, histological examination was performed on the kidney.
Results: Treatment with T-5224 decreased serum TNF-α and HMGB-1 levels and increased survival after LPS injection.
Furthermore, T-5224 treatment decreased serum BUN and creatinine concentrations but increased serum IL-10
concentration. LPS-induced pathological changes in kidney were attenuated by T-5224 treatment.
Conclusions: These results suggest that T-5224, a selective inhibitor of c-Fos/AP-1, inhibits expression of early and late
proinflammatory cytokines, protecting mice from LPS-induced lethality. T-5224 is a potential approach for decreasing
lethality in sepsis-induced AKI.
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Background
Sepsis is characterized by a severe systemic inflam-
matory response to infection. Sepsis causes multiple
organ failure, and acute kidney injury (AKI) is a crit-
ical complication of sepsis [1]. Sepsis-induced AKI
decreases survival prognosis and is associated with
70–80 % mortality in the intensive care unit [2].
This unacceptably high mortality rate has inspired
researchers to better understand the molecular
pathogenesis of AKI and seek improved therapeutic
interventions.
Until recently, inflammatory reactions by cytokine
cascades and oxidative stress were proposed as the
molecular pathogenesis of sepsis-induced AKI [3].
High mobility group B-1 (HMGB-1) is a ubiquitous
nuclear protein present in almost all eukaryotic cells,
where it regulates transcription under normal condi-
tions [4]. More importantly, unlike other proinflamma-
tory cytokines such as tumor necrosis factor-alpha
(TNF-α) and interleukin-1 beta (IL-1β), HMGB-1 was
mplicated as a “late mediator” of lethal systemic inflam-
mation in cytokine-mediated disease initiated by the
Gram-negative bacterial product endotoxin [lipopoly-
saccharide (LPS)] [5]. Administration of a HMGB-1
neutralizing antibody, or of a drug that neutralizes
HMGB-1, affords significant protection [5, 6]. These
studies suggested that HMGB-1 may serve as a more
effective therapeutic target for the treatment of lethal
sepsis-induced AKI as opposed to other proinflamma-
tory cytokines [7].
Activator protein-1 (AP-1) is a transcription factor
composed of c-Fos and c-Jun proteins. C-Fos/AP-1
controls transactivation of multiple proinflammatory
cytokines via promoter AP-1 binding motifs [8].
Tsuchida et al. designed and synthesized a selective
inhibitor of c-Fos/AP-1 by three-dimensional (3D)
pharmacophore modeling based on an X-ray crystal
structure of the basic region-leucine zipper (bZIP)
domain of the AP-1-DNA complex [9]. T-5224 is a
de novo small molecule selective inhibitor of c-Fos/
AP-1 that controls gene expression of multiple proin-
flammatory cytokines. Aikawa et al. demonstrated that
oral administration of this selective inhibitor resolved
collagen-induced arthritis in mice by inhibiting proinflam-
matory cytokines (e.g., IL-1 β, IL-6) [10]. Furthermore, we
previously demonstrated that T-5224 prevented AKI by
inhibiting serum early proinflammatory cytokines (TNF-α,
IL-1β, IL-6) in a non-lethal model (LPS 6 mg/kg body
weight) [11].
Based on selective inhibition of AP-1 signaling to
control expression of proinflammatory cytokines, we
sought to investigate whether T-5224 improved mor-
tality by inhibiting early (TNF-α) and late (HMBG-1)
responses in lethal LPS-induced AKI.
Methods
Animal experiments
Male 8-week-old C57BL/6 mice (20–25 g) were obtained
from CLEA Japan, Inc. (Tokyo, Japan), housed in a
specific pathogen-free grade environment, and provided
food and water ad libitum under a 12-h light/dark cycle.
All animal experiments were performed in accordance
with the National Institutes of Health Guidelines under
protocols approved by the Institutional Animal Care and
Use Committee (permission number: P090416) of Kobe
University (Kobe, Japan).
Reagents and drugs
LPS (Escherichia coli serotype 0111:B4) was purchased
from Sigma-Aldrich (St. Louis, MO, USA) and dissolved
in normal saline for administration to mice. T-5224,
which is 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-
[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl} pro-
pionic acid, was synthesized and generously donated by
Toyama Chemical Co., Ltd. (Toyama, Japan). T-5224
was dissolved in polyvinylpyrrolidone (PVP) solution.
Experimental design
Mice were randomly divided into four experimental
groups: the control group (n = 58), administered PVP
solution orally immediately after i.p. saline injection;
the LPS group (n = 58), administered PVP solution
orally immediately after i.p. LPS (10 mg/kg body
weight) injection; the LPS + T-5224 group (n = 58),
administered T-5224 (300 mg/kg body weight) immedi-
ately after LPS injection; and the T-5224 group (n = 58),
administered T-5224 (300 mg/kg) orally, immediately
after i.p. saline injection. In a series of preliminary studies
(n = 7), we measured the TNF-α concentration at 1.5 h
(2953.0 (2390.1–3659.9), pg/ml) and 3 h (742.6
(672.9–820.7), pg/ml) after LPS (10 mg/kg) injection.
Furthermore, the effects of 30 mg/kg and 300 mg/kg
of T-5224 on the serum TNF-α concentration 1.5 h
after LPS injection were 2473.0 (2322.5–2658.9) pg/ml
and 1702.0 (1610.6–1743.4) pg/ml.
Thus, we decided that the peak timing of serum TNF-
α concentration was at 1.5 h after LPS injection and the
optimal dose of T-5224 was 300 mg/kg.
Measurement of serum TNF-α concentration
To measure the serum TNF-α concentration after LPS
injection, 1 ml of blood was collected at 1.5 h after LPS
injection via the femoral artery (n = 7 for each group).
Blood was centrifuged (2500 × g, 10 min, 4 °C) and the
serum collected and stored at −80 °C until analysis.
Enzyme-linked immunosorbent assays (ELISAs) were
carried out using a TNF-α ELISA kit (R&D systems,
Minneapolis, MN, USA), according to the manufac-
turer’s protocols.
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Survival study and measurement of serum HMGB-1
To examine the protective effect of T-5224 on the survival
rate after LPS injection, the survival rate was recorded
every 6 h for 3 days in four groups (n = 20 for each
group).
To measure serum HMGB-1 concentrations, 1 ml of
blood was collected 18 h after LPS injection via the
femoral artery (n = 7 for each group) [5]. ELISAs were car-
ried out using a HMGB-1 ELISA kit (Shino-Test, Sagami-
hara, Kanagawa, Japan), according to the manufacturer’s
protocols.
Measurement of serum IL-10 serum and blood urea nitro-
gen (BUN) and creatinine concentrations
One milliliter of blood samples were collected at 1.5 h
(serum IL-10, n = 7 for each group) or 18 h (serum BUN
and creatinine, n = 7 for each group) after LPS injection via
the femoral artery. Blood was centrifuged (2500 × g,
10 min, 4 °C) and the serum collected and stored at −80 °C
until analysis. Serum IL-10 was measured using ELISA kits
(Life Technologies, Carlsbad, CA, USA), according to the
manufacturers’ protocols. The BUN and Cr concentra-
tions were commercially analyzed (Special Reference
Laboratories, Tokyo, Japan).
Histological evaluation
Mice were sacrificed and kidneys were removed for
histopathological observation at 24 h after LPS injection
(n = 10 for each group). We evaluated the histology in 5
mice among 10 mice that we used for histological analysis
study. A portion of the kidney was fixed immediately in
10 % formalin and embedded in wax according to a stand-
ard protocol. Samples were cut on a microtome into
sections of 4 μm and stained with hematoxylin and eosin
(H & E) to observe general cell morphology. Samples were
examined with a light microscope.
Statistical analyses
Statistical analyses were carried out using Kruskal-Wallis
test for non-parametric data with Dunn’s multiple com-
parisons posttest. The survival curves compared using
Kaplan-Meier methods followed by a log-rank test. Data
are represented as medians with interquartile ranges. P <
0.05 was considered significant.
Results
Changes in serum TNF-α concentration
F-α is an inflammatory cytokine and plays an important
role in LPS-induced early inflammatory responses. We
examined the effect of T-5224 on serum TNF-α concentra-
tion at 1.5 h after LPS injection (Table 1). Serum TNF-α
concentration in the LPS group (2738.0 (2429.7–3377.2)
pg/ml) was higher than that of controls (39.5 (36.0–47.0)
pg/ml, P < 0.001), and oral administration of T-5224
(300 mg/kg) immediately after LPS injection decreased
serum TNF-α concentrations (1533.0 (1453.9–1602.6) pg/
ml, P < 0.01, Table 1).
Changes of serum HMGB-1 concentration and survival
HMGB-1 is a late mediator of lethal systemic inflamma-
tion in animal models of cytokine-mediated sepsis.
Activated macrophages release HMGB-1 after a lag of
12–18 h [5]. Serum HMGB-1 concentration 18 h after
LPS injection was significantly higher than that of
controls (Table 1), and oral administration of T-5224 im-
mediately after LPS injection inhibited serum HMGB-1
increases. Survival rates at 72 h post-LPS injection were
40 % (Fig. 1). However, in mice treated with T-5224,
survival rates at the corresponding time point after LPS
injection increased to 80 % (Fig. 1, P < 0.01).
Changes in serum IL-10 concentration
We also examined serum concentrations of IL-10, an anti-
inflammatory cytokine, 1.5 h after LPS injection [12], which
were elevated in the LPS (1361.0 (1256.3–1603.9) pg/ml)
relative to the control group (59.5 (48.8–62.9) pg/ml, P <
0.001). In addition, the concentration of IL-10 induced in
LPS +T-5224 (3165.0 (2897.8–3400.8) pg/ml, P < 0.001,
Table 1) increased compared with that of the LPS group.
Changes in serum BUN and creatinine concentrations
We examined serum BUN and creatinine concentrations
to evaluate kidney function. In the LPS group, serum
BUN and creatinine concentrations were significantly
increased at 18 h compared with those in the control
group. The administration of T-5224 reduced serum
BUN and creatinine concentrations at 18 h after LPS
injection (Table 1).
Histological changes in kidney tissue
To evaluate histopathological changes of the kidney,
tissue sections were stained with H & E. Examination in
the LPS group revealed mild morphological damage,
including necrotic degeneration with pyknotic nuclei. In
contrast, treatment with T-5224 reduced the extent of
kidney injury (Fig. 2).
Discussion
We investigated whether T-5224 improved mortality by
inhibiting the early (TNF-α) and late (HMBG-1) proinflam-
matory response in lethal LPS-induced AKI, based on the
idea that T-5524 inhibits c-Fos/AP-1, which transactivates
proinflammatory cytokines via promoter AP-1 binding
motifs [10]. Our results demonstrate that T-5224 blocks
serum TNF-α, HMGB-1, BUN, and creatinine concen-
trations, reducing mortality of LPS-induced AKI. These
findings suggest that T-5224 may be protective against
lethal LPS-induced AKI.
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It is well known that inflammation plays a key role in the
pathogenesis and development of sepsis-induced AKI.
There is an exaggerated stimulation of the normal host
response to eradicate invasive pathogens, leading to exces-
sive release of inflammatory mediators. LPS, derived from
enterobacteria, binds to toll-like receptor (TLR) 4, which
triggers a series of signaling pathways leading to NF-κB or
AP-1 activation and inflammatory mediator gene expres-
sion [13]. Various methods have been used to block these
signaling pathways. However, clinical trials with anti-
cytokine agents, such as anti-TNF-α antibodies and soluble
IL-1 receptor antagonists, have proven ineffective in the
treatment of sepsis [14, 15]. These findings suggest that
sepsis is not only a disease of a single inflammatory
cytokine but that it involves complex pathways involving
various cytokines, suggesting that blocking only one
cytokine may not be curative because of the orchestrated
cross-talk among inflammatory mediators. Meanwhile, it
has been shown that LPS stimulation activates NF-κB,
leading to target gene transcription [16]. Various methods
have been used to suppress NF-κB. However, these
methods have been limited in their clinical use because of
their low specificity [17, 18].
C-Fos/AP-1 directly controls the expression of inflam-
matory cytokines by binding to AP-1 motifs in the
promoters of these genes [19]. T-5224 was designed and
synthesized to be a selective inhibitor of c-Fos/AP-1 using
3D pharmacophore modeling based on a crystal structure
of the AP-1-DNA complex [9] and found that selective
inhibition of c-Fos/AP-1 resolves arthritis [10]. We have
Table 1 Change in serum TNF-α, HMGB-1, IL-10, and BUN and creatinine concentrations
Serum TNF-α
(pg/ml, n = 7)
Serum HMGB-1
(ng/ml, n = 7)
Serum IL-10
(pg/ml, n = 7)
Serum BUN Serum creatinine
(mg/dl, n = 7)
Control 39.5 (36.0–47.0) 19.8 (19.0–23.4) 59.5 (48.8–62.9) 29.6 (27.2–30.7) 0.11 (0.10–0.12)
LPS 2738.0 (2429.7–3377.2)** 169.8 (166.7–224.5)** 1361.0 (1256.3–1603.9)** 98.8 (95.3–102.8)** 0.35 (0.34–0.38)**
LPS + T-5224 1533.0 (1453.9–1602.6)**,## 132.8 (119.1–140.6)**,## 3165.0 (2897.8–3400.8)**,## 70.5 (68.4–76.8)**,## 0.28 (0.22–0.29)**,##
T-5224 32.0 (30.0–34.0) 19.4 (17.9–21.1) 64.9 (55.6–70.1) 28.0 (24.0–28.7) 0.10 (0.09–0.11)
Control: mice received PVP solution orally immediately after saline injection. LPS: mice received PVP solution orally immediately after LPS (10 mg/kg) injection.
LPS + T-5224: mice received T-5224 (300 mg/kg) immediately after LPS injection. T-5224: mice received T-5224 (300 mg/kg) after saline injection. Data are
represented as medians with interquartile ranges
TNF-α tumor necrosis factor-alpha, HMGB-1 high mobility group box-1, IL-10 interleukin-10, BUN blood urea nitrogen
**P < 0.01 compared with control group. ##P < 0.01 compared with LPS group
Fig. 1 Effect of T-5524 on survival. T-5224 prevents LPS-induced lethality. The survival rate was recorded every 6 h for 3 days. Open squares are control
mice. Closed circles are LPS mice. Closed squares are LPS + T-5224 mice. Open circles are T-5224 mice. n = 20 for each group. ##P < 0.01 compared with
LPS mice
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previously shown that T-5224 inhibits serum proinflam-
matory cytokines, such as TNF-α, IL-1β, and IL-6, in non-
lethal LPS-induced AKI in mice (LPS 6 mg/kg body
weight) [11]. However, we did not evaluate survival. In the
present study, we demonstrated that T-5224 inhibited
serum TNF-α expression and improved survival in lethal
LPS-induced AKI (LPS 10 mg/kg body weight). HMGB-1
is classically known as an intracellular DNA-binding
protein, released by endotoxin-stimulated activated
macrophages after 12–18 h. HMGB-1 has been implicated
as a late mediator of lethal systemic inflammation in an
LPS-induced septic model [5]. Ulloa et al. previously
reported that ethyl pyruvate prevented the release of early
(TNF-α) and late (HMGB-1) inflammatory mediators
through the transcription factor nuclear factor-kappa B
(NF-κB) signal transduction pathway [6]. Our study shows
that lethal LPS-induced AKI resulted in higher serum
HMGB-1 concentrations and that T-5224 inhibits serum
HMGB-1 concentration, leading to reduced mortality in
mice with LPS-induced AKI. This finding is consistent
with previous studies [5, 6]. Based on our study and
previous studies, HMGB-1 is thought to be a more
effective therapeutic target for the treatment of lethal
LPS-induced AKI as well as other proinflammatory
cytokines. However, T-5224 did not completely inhibit
serum TNF-α expression in our study. One potential
explanation for this could be that genes encoding inflam-
matory cytokines are transcriptionally activated through
NF-κB and AP-1 activation, and that T-5224 selectively
inhibits the DNA-binding activity of c-Fos/c-Jun, without
affecting binding of other transcription factors such as
NF-κB.
In sepsis patients, immunosuppression occurs in addition
to hyperinflammation and can lead to lethal infection [20].
Regulation of immunosuppression could also be more
beneficial than suppression of hyperinflammation. T-5224
treatment immediately after LPS injection increased serum
IL-10 concentrations. IL-10 is an anti-inflammatory
cytokine that decreases production of several inflammatory
cytokines, such as TNF-α, IL-1β, and IL-6, preventing
subsequent death [21]. The balance between inflammation
and immune response following T-5224 treatment might
affect the survival rate. Furthermore, T-5224 may have
potential benefits in patients with the immunosuppression
state. However, further studies are needed to evaluate this
possibility.
The serum BUN and creatinine concentrations were used
in this study as indicators of renal function in LPS-induced
AKI. The increase of serum creatinine level and oliguria
during sepsis often appears after the window of opportunity
Fig. 2 Effects of T-5224 on renal histopathology. T-5224 attenuated mild morphological damage, including necrotic degeneration with pyknotic nuclei.
The sections shown were harvested 24 h after LPS injection and stained with H & E. a Control: mice received PVP solution orally immediately after i.p. saline
injection. b LPS: LPS mice received PVP solution orally immediately after i.p. LPS (10 mg/kg body weight) injection. LPS caused necrotic degeneration with
pyknotic nucleus (arrow head). c LPS + T-5224: LPS + T-5224 mice received T-5224 (300 mg/kg) immediately after LPS injection. There was less necrotic
degeneration following T-5224 treatment. d T-5224: T-5224 mice received T-5224 (300 mg/kg) after i.p. saline injection. Scale bars = 100 μm. n= 5 for
each group
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for effective therapy. Because septic AKI is characterized by
a distinct pathophysiology, new biomarker for early detec-
tion of AKI is needed [22]. A recent study demonstrated
that septic AKI patients have higher detectable plasma
neutrophil gelatinase-associated lipocalin compared with
non-septic patients [23]. The utility of such biomarkers
may be of particular importance in lethal septic patients,
because early detection of AKI would significantly decrease
morbidity and mortality related to AKI [24].
Sepsis is characterized by hyperactivation of inflamma-
tory cascade and causes organ dysfunction in vital organs
such as the lung, liver, and kidney. C-Fos/AP-1 controls the
expression of inflammatory cytokines including TNF-α by
binding directly to AP-1 motifs in the promoters of these
genes [19]. T-5224 is a new drug that selectively inhibits
c-Fos/AP-1 binding to DNA. In addition to the effects
of T-5224 on LPS-induced AKI [11], we demonstrated
that T-5224 attenuated LPS-induced liver injury in
mice [25]. T-5224 may beneficial effects in sepsis-induced
organ dysfunctions. Further experimental studies will be
needed to better understand the potential effects of T-
5224 on other sepsis-induced organ dysfunctions such as
sepsis-associated acute respiratory distress syndrome.
There were three limitations in our study. First, we did
not investigate whether T-5224 specifically binds c-Fos/
AP-1 in renal cells. Additional studies will be required to
elucidate whether T-5524 inhibits AP-1 activation in
LPS-stimulated renal cells. The second limitation was
oral administration and the timing and of T-5524. We
orally administered T-5224 after LPS injection. We did
not measure the plasma concentration of T-5224 after a
single oral administration of T-5224 in this study. Aikawa
et al. demonstrated that the maximum plasma concentra-
tion of T-5224 was 240 ng/ml after a single oral administra-
tion of T-5224 (10 mg/kg body weight) in collagen-induced
arthritis in mice. T-5224 at 1.5 h after a single oral ad-
ministration maintained high concentration [10]. There-
fore, we assumed that the plasma concentration of T-5224
(300 mg/kg) at 1.5 h after LPS injection was effective
enough. Further studies are needed to evaluate this
assumption. In addition, sepsis treatments are started
several hours after onset in clinical setting. Because most
patients with severe sepsis could not take a meal, intraven-
ous administration of T-5524 to treat persistent inflamma-
tion is needed to be considered. This limitation is also
issued to address in future studies. The last limitation was
the histological evaluation. We did not evaluate quantita-
tively histopathological differences among groups, because
sample number is small. Further studies are needed to
confirm our data, based on morphology.
Conclusions
This study demonstrated that a single dose of T-5224
improved the survival by inhibiting expression of a
proinflammatory cytokine (TNF-α) and a late mediator
(HMGB-1) in lethal LPS-induced AKI. The results of the
present study provide new fundamental insights, suggesting
that T-5224 may be a novel therapeutic agent for treating
sepsis-induced AKI.
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